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Purpose or Objective: Neck fibrosis is an important 
complication following radio(chemo-)therapy (R(C)T) for head 
and neck cancer (HNC). The purpose of this study was to find 
a parameter that could predict late neck fibrosis and to make 
a multivariate model to predict neck fibrosis grade ≥ 2 
(fibrosis RTOG2-4) at 6 months following R(C)T for HNC. 
 
Material and Methods: We prospectively included 193 
patients in 5 different RT centers for a randomized controlled 
trial. On this patient-population we tested age, sex, T/N 
stage, tumor site, concomitant chemotherapy, upfront neck 
dissection, neo-adjuvant chemotherapy, accelerated RT, 
smoking (never-former-current), alcohol abuse (never-
former-current), the dose prescribed to the elective neck and 
erythema at the end of treatment for their potential to 
predict neck fibrosis RTOG2-4 6 months after the end of 
treatment. Fisher's exact test and Mann-Whitney U test were 
used for testing the association between fibrosis grade 0-1 
versus fibrosis grade 2-4 with categorical or continuous 
variables, respectively. A stepwise selection procedure was 
made to determine the best combination of predictor 
variables for fibrosis RTOG2-4 at 6 months. The area under 
the ROC curve (AUC) was determined for the selected model. 
Additionally a bootstrap-corrected AUC value was calculated. 
This AUC value corrects for over optimism resulting from the 
fact that model construction and model validation were 
performed on the same data set. All tests are two-sided; a 5% 
significance level is considered for all tests. 
 
Results: Upfront neck dissection (p<0.01), erythema at the 
end of R(C)T ≥ grade 3 (p<0.01), increasing N stage (p<0.01) 
and cancer of unknown primary (p=0.02) are significantly 
associated with the incidence of fibrosis RTOG2-4 at 6 
months in our patient population in univariate analysis. 
Upfront neck dissection and erythema grade ≥3 at the end of 
R(C)T were identified for our model using a stepwise 
selection procedure. Additionally, increasing N stage was 
selected as an independent predictor variable (Table 1).  
 
The AUC for this model containing upfront neck dissection, 
erythema at the end of treatment and smoking status was 
0.92; the bootstrap-corrected AUC was 0.90. The risk for 
fibrosis RTOG2-4 at 6 months can be calculated using the 
following formula: 
 
 
 
Conclusion: A model for the prediction of fibrosisRTOG2-4 
following R(C)T for head and neck cancer is presented withan 
AUC of 0.92. Erythema at the end of R(C)T is associated with 
RTOG2-4 fibrosisat 6 months. 
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Purpose or Objective: To determine if the remaining 
submandibular gland volume after surgery is a prognostic 
factor for late xerostomia after postoperative radiotherapy 
(PORT) for head and neck cancer (HNC). 
 
Material and Methods: This prospective cohort study 
consisted of 198 HNC patients who received PORT. The 
primary endpoint was CTCAE v4.0 grade 2 or higher physician 
rated xerostomia at 6 months after completing PORT 
(XERM6). From a set of factors deemed relevant in relation to 
the endpoint (patient characteristics, treatment details, 
surgical data, dosimetric data of major and minor salivary 
glands and oral cavity) a subset of candidate factors was 
selected, using expert knowledge and model exploration. 
Manual stepwise logistic regression was performed with the 
aim to build a strong and valid parsimonious prediction model 
for XERM6. 
 
Results: XERM6 was observed in 54 patients (27.3%). The 
number of remaining submandibular glands was 2 (n=42, 
average remaining volume: 18.7 cm³); 1 (n=105, average 
remaining volume: 9.0 cm³); or 0 (n=51). Patients underwent 
surgery in the oral region (n=154) or in the hypopharyngeal / 
laryngeal region (n=44). The multivariable analysis revealed 
the following independent prognostic factors for the final 
model: baseline xerostomia ≥ grade 1 (OR: 2.978, 95%CI: 
1.363-6.504); ipsilateral parotid mean dose (OR: 1.035 per 
Gy, 95%CI: 1.007-1.065); contralateral parotid mean dose 
(OR: 1.019 per Gy, 95%CI: 0.984-1.056); and the remaining 
total submandibular gland volume (OR: 0.908 per cm³, 95%CI: 
0.855-0.964). This model calibrated well with the observed 
data (Hosmer & Lemeshow test: p = 0.798) and had a good 
performance (Nagelkerke adjusted R²: 0.223, and ROC-AUC: 
0.758). Effect sizes and performance measures were not 
significantly different after internal validation using cross-
validation. 
 
Conclusion: With a similar dose in the parotid glands, the 
risk of late xerostomia increased significantly with less 
remaining submandibular gland volume after surgery. This 
effect is not accounted for in excisting models for late 
xerostomia. The proposed model is the first model 
specifically valuable for predicting late xerostomia in HNC 
patients receiving PORT. 
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Purpose or Objective: To investigate the body image in head 
and neck cancer patients treated with radiotherapy. 
 
Material and Methods: A cross-sectional survey of 150 
patients with head and neck cancer, 60 patients were 
nasopharyngeal cancer (NPC) treated by definite 
radiotherapy without surgery, and 90 patients were oral 
cavity cancer (OCC) treated by radical surgery plus adjuvant 
radiotherapy. All participants completed a 10-item Body 
Image Scale (BIS) to assess the body image dissatisfaction. In 
all patients, the clinical and socio-demographic variables 
were cancer type, age, gender, partnership, education, and 
employment. In OCC patients, the socio-demographic 
variables were the same, and clinical variables were facial 
skin sacrificed, mouth angle sacrificed, glossectomy, 
maxillectomy, and mandibulectomy. ANOVA, t-test, and 
multiple regression were used to evaluate the relationships 
between these variables and BIS. 
 
Results: In all patients, the cancer type (NPC vs. OCC) was 
the strongest independent predictor of BIS. The non-
surgically treated NPC patients had significantly better body 
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image outcome than the surgically treated OCC patients. 
Education was also an independent factor for BIS. In OCC 
patients, facial skin sacrificed, mouth angle sacrificed, 
maxillectomy, and mandibulectomy were significantly 
associated with BIS. Using multivariate analysis, inferior 
maxillectomy and segmental mandibulectomy were the 
independent poor prognosticators of body image outcome in 
OCC patients. 
 
Conclusion: The radical surgery for head and neck cancer 
patients has a significant impact on body image, especially 
those with facial bone destruction. These findings could be 
used to guide psychosocial interventions targeting body 
image disturbance for patients with head and neck cancer. 
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Purpose or Objective: Head and neck cancer patients 
treated with chemoradiation are at risk for developing 
trismus (reduced mouth opening). Trismus is often a 
persisting side-effect and difficult to manage. It impairs 
eating, speech and oral hygiene, affecting quality of life. 
Although several studies identified the masseter muscle (MM) 
as one of the main organs at risk, currently this structure is 
rarely considered during treatment planning. Prospective 
studies for chemoradiation are lacking. The aim of our study 
was to quantify the relationship between radiation dose to 
the MM and development of radiation-induced trismus in an 
IMRT-VMAT population. 
 
Material and Methods: The 93 patients in this study 
participated in a prospective preventive exercise program to 
preserve oral functioning between 2006-2013. All received 
concomitant high-dose chemotherapy during VMAT- or IMRT-
radiotherapy (70 Gy in 35 fractions). Tumor locations were 
mainly oropharynx (37%) and hypopharynx (33%). Maximum 
interincisor mouth opening was measured before and 
approximately 10 weeks after the end of treatment. Bilateral 
delineations of the MM were available from 2 retrospective 
studies. Patients were excluded if trismus was present at 
baseline, or if gross tumor infiltration of the MM was present 
on CT evaluation. Evaluated outcomes were trismus (mouth 
opening ≤ 35 mm) and decrease in mouth opening. Logistic 
regression (using maximum likelihood) was performed. 
 
Results: At the first evaluation, 6-12 weeks post-treatment, 
fourteen patients had developed radiation-induced trismus 
(15%). On average, mouth opening decreased with 4.1 mm, or 
8.2 % relative to baseline. Mean dose to the ipsilateral MM 
was a stronger predictor for trismus than mean dose to the 
contralateral MM, as indicated by the lowest -2 log likelihood 
(Table 1). Figure 1A shows the correlation between the 
ipsilateral mean masseter dose and the relative decrease in 
mouth opening, with trismus cases indicated in red. No 
trismus cases were observed in 33 patients (35%) with a mean 
dose to the ipsilateral MM < 20 Gy. The risk of trismus in the 
other 60 patients (65%) increased with higher mean doses to 
the ipsilateral MM. Figure 1B shows the fitted NTCP curve as 
a function of the mean dose, with a TD50 of 55 Gy. The 
actual incidence (with 1 SE) of trismus cases within 5 dose 
bins is indicated as well, showing a good correspondence with 
the NTCP fit with a relatively large uncertainty in the dose 
area > 50 Gy. Patients with tumors located in the oropharynx 
were at highest risk. 
 
Conclusion: The risk of trismus can be established with the 
mean dose to the ipsilateral masseter muscle. The majority 
of head and neck cancer patients could benefit from dose 
reduction to the masseter muscles to prevent trismus, 
especially patients with a mean dose to the ipsilateral 
masseter > 20 Gy. Further development of a NTCP model 
could identify dose objectives to guide treatment planning. 
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Purpose or Objective: Oral mucositis (OM) is the most 
frequent and severe acute toxicity of chemoradiotherapy 
(CRT) in head and neck cancer (HNC) patients. In preclinical 
